Assistance Publique-Hôpitaux de Marseille, Laboratoire d'Immunologie, Hôpital de La Conception, Marseille, France.
Pediatr Allergy Immunol. 2011 Sep;22(6):600-7. doi: 10.1111/j.1399-3038.2011.01166.x. Epub 2011 Jul 8.
Mast cells participate in immune defense and allergic disease. At baseline, serum tryptase levels primarily reflect mast cell burden, while mast cell degranulation leads to granule tryptase release, which may be detectable as a transitory elevation of serum tryptase levels. Thus, mast cell burden and mast cell activity are reflected by serum tryptase levels, but reports are scarce in infants under 1 yr. We aimed at defining levels of total serum tryptase levels in this population.
Total serum tryptase levels (ImmunoCAP; Phadia) were measured in 372 sera from infants younger than 1 yr. Two hundred and forty-two sera came from non-atopic, non-allergic infants in good condition, who had blood drawn for routine follow-up or diagnosis of illnesses that are not known to induce changes in serum tryptase levels. Seventy-two sera were from atopic and/or allergic infants, and 58 sera were from non-atopic, non-allergic infants requiring intensive care.
Median serum tryptase levels were highest in infant2s under 3 months (6.12 ± 3.47 μg/l) and gradually decreased before reaching levels similar to those described in adults and older children (3.85 ± 1.8 μg/l between 9 and 12 months). Atopic/allergic status was associated with even higher tryptase levels (14.20 ± 10.22 μg/l in infants younger than 3 months). Intensive care patients had lower levels of serum tryptase (4.12 ± 3.38 μg/l in infants younger than 3 months). Longitudinal follow-up was performed in 27 patients and showed tryptase levels decrease over time in individual patients. Infants'sex was not found to interfere with serum tryptase levels.
Total serum tryptase levels are significantly higher in younger infants compared with older ones. In infants of the same age, serum tryptase levels may vary according to the clinical condition and thus suggest mast cell involvement in the physiologic as well as in the allergic immune responses of young infants.
肥大细胞参与免疫防御和过敏性疾病。在基线时，血清类胰蛋白酶水平主要反映肥大细胞负担，而肥大细胞脱颗粒导致颗粒类胰蛋白酶释放，这可能表现为血清类胰蛋白酶水平的短暂升高。因此，血清类胰蛋白酶水平反映了肥大细胞负担和肥大细胞活性，但在 1 岁以下婴儿中的报道很少。我们旨在确定该人群的总血清类胰蛋白酶水平。
测量了 372 份年龄小于 1 岁的婴儿血清中的总血清类胰蛋白酶水平（ImmunoCAP；Phadia）。242 份血清来自非特应性、非过敏性、身体状况良好的婴儿，这些婴儿因常规随访或诊断已知不会引起血清类胰蛋白酶水平变化的疾病而采血。72 份血清来自特应性和/或过敏性婴儿，58 份血清来自需要重症监护的非特应性、非过敏性婴儿。
3 个月以下婴儿的血清类胰蛋白酶水平中位数最高（6.12 ± 3.47 μg/l），然后逐渐下降，直到达到与成人和较大儿童相似的水平（9 至 12 个月时为 3.85 ± 1.8 μg/l）。特应性/过敏性状态与更高的类胰蛋白酶水平相关（3 个月以下婴儿为 14.20 ± 10.22 μg/l）。重症监护患者的血清类胰蛋白酶水平较低（3 个月以下婴儿为 4.12 ± 3.38 μg/l）。对 27 例患者进行了纵向随访，结果显示个体患者的类胰蛋白酶水平随时间降低。未发现婴儿的性别会干扰血清类胰蛋白酶水平。
与较大婴儿相比，较小婴儿的总血清类胰蛋白酶水平显著更高。在年龄相同的婴儿中，血清类胰蛋白酶水平可能根据临床情况而有所不同，因此提示肥大细胞参与了年轻婴儿的生理和过敏性免疫反应。
